Immunogenicity and reactogenicity of an inactivated hepatitis A vaccine in Indian adults

National Medical Journal of India

Volumn 12, Issue 6, 1999, Pages 268-269

  Das, K ^a   Jain, A ^a   Gupta, R K ^a   Kar, P ^a,b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b DII/M 2755 ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FEVER; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; PAIN; VACCINATION; VIRUS HEPATITIS;

ADOLESCENT; ADULT; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS ANTIBODIES; HUMANS; INDIA; MALE; MIDDLE AGED; VIRAL HEPATITIS VACCINES;

EID: 0033390791     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Roy P, Prasad SR, Pal SR. One-year surveillance of sporadic hepatitis A in children at Chandigarh. Indian J Med Res 1987;86:626-8.
2. Tandon BN, Gandhi BM, Joshi YK, Irshad M, Gupta H. Hepatitis virus non-A, non-B the cause of a major public health problem in India. Bull World Health Organ 1985;63:931-4.
3. Frosner GG, Papaevangelou G, Butler R, Iwarson S, Lindholm A, Courouce-Pauty H, et al. Antibody against Hepatitis A in seven European countries. I. Comparison of prevalence in different age groups. Am J Epidemiol 1979;110:63-9.
4. Perez TE, Cilla EG, Urbieta M, Garcia BM. Prevalence of Hepatitis A virus infection in Spain. Scan J Infect Dis 1988;20:113.
5. Kremastinou T, Kalapothaki V, Trichopoulos D. The changing epidemiologic pattern of hepatitis A infection in urban Greece. Am J Epidemiol 1986;120:703-6.
6. Mele A, Pasquini P, Pana A. Hepatitis A in Italy: Epidemiology and suggestions for control. Ital J Gastroenterol 1991;23:341-3.
7. Marinho RT, Valente AR, Ramatho FJ, de Moura MC. The changing epidemiological pattern of hepatitis A in Lisbon, Portugal. Eur J Gastroenterol Hepatol 1997;9: 795-7.
8. Dhawan PS, Shah SS, Alvares JF, Khar A, Shankaran, Kandoth PW, et al. Seroprevalence of Hepatitis A virus in Mumbai and immunogenicity and safety of hepatitis A vaccine. Indian J Gastroenterol 1998;17:16-8.
9. Das K, Jain A, Gupta S, Kapoor S, Gupta RK, Chakrovarty A, et al. The changing epidemiological pattern of hepatitis A in the urban population of India: Emergence of a trend similar to the European countries. Trop Med Int Health 1999 (In press).
10. Gay NJ, Morgan Capner P, Wright J, Farrington CP, Miller E. Age-specific anti-body prevalence of hepatitis A in England: Implications for disease control. Epidemiol Infect 1994;113:113-20.
11. Clemens R, Safary A, Hepbum A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. JAMA 1994;271:1328-34.
12. Andre FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety of an inactivated hepatitis A vaccine: Rationale and summary of finding. Vaccine 1992;10 (Suppl 1):160-8.
13. Arankalle VA, Tsarev SA, Chadha MS, Alling DW, Emerson SU, Banerjee K, et al. Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis 1995;171:447-50.
14. Hadler SC. Global impact of hepatitis A virus infection changing patterns. In: Hollinger FB, Lemon SM, Margolis H (eds.) Viral hepatitis and liver disease. Baltimore:Williams & Wilkins, 1999:14-20.
15. John TJ, Chandy GM. What priority for prevention of hepatitis A in India? Indian J Gastroenterol 1998;17:2-3.
16. Fisch A, Cadillhac P, Vidor E, Frazuck T, Dublanchet A, Lafaix C. Immunogenicity and safety of a new inactivated hepatitis A vaccine: A clinical trial on the comparison of administrative route. Vaccine 1996;14:1132-6.
17. Fan PC, Chang MH, Lee P, Safary A, Lee CY. Follow up of immunogenicity of an inactivated hepatitis A vaccine in healthy children: Results after 5 years. Vaccine 1998;16:232-5.
18. Lo YC, Lee SS, Wong KS, Lin WL. Inactivated hepatitis A vaccine in healthy Chinese adults. J Intern Med 1996;239:173-6.
19. Reumann PD, Kubilis P, Hurni M, Brown L, Valia D. Effect of age and weight on the response to formalin inactivated alum adjuvanted hepatitis A vaccine in healthy adults. Vaccine 1997;15:1157-61.
20. Maiwald H, Jilg W, Bock HL, Loscher T, Sonnenburg F. Long-term persistence of anti-HAV antibodies following active immunisation with hepatitis A vaccine. Vaccine 1997;15:346-8.
21. Sandman L, Davidson M, Krugman S. Inactivated hepatitis A vaccine: A safety and immunogenicity study in health professionals. J Infect Dis 1995;171 (Suppl 1): 550-2.
22. Balcarek KB, Bagley R, Pass RF, Schiff ER, Kause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995;171 (Suppl 1):S50-S52.
23. Victor J, Knusen JD, Nielsen LP. Hepatitis A vaccine: A new convenient single dose scheduled with booster when long term immunisation is warranted. Vaccine 1994; 12:1327-9.
24. Pooverawan Y, Theamboonlers A, Safary A. Single dose hepatitis A vaccination: Comparison of different dose levels in adolescents. Vaccine 1996;14:1092-4.
25. Westblom TU, Gudipati S, Rousse CD, Midkiff BR, Belshe RB. Safety and immunogenicity of an inactivated hepatitis A vaccine: Effect of dose and vaccination schedule. J Infect Dis 1994;169:996-1001.
26. Goilav C, Zuckerman J, Lafrenz M, Vidore E, Lauwers S, Ratheau C, et al. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study. J Med Virol 1995;46:287-92.
27. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271: 1328-34.